Drugs / SZEY-2108
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06055777 Comparator | Sep 2023 → May 2024 | infectious disease | Suzhou Erye Pharmaceutical Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SZEY-2108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06055777 ↗ |
| Route | Intravenous | “administrated with SZEY-2108 or placebo by single intravenous infusion” NCT06055777 ↗ |